Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects.
Saved in:
| Title: | Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects. |
|---|---|
| Authors: | Rao VS; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut., Ivey-Miranda JB; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.; Hospital de Cardiologia, Instituto Mexicano del Seguro Social, Mexico City, Mexico., Cox ZL; Department of Pharmacy Practice, Lipscomb University College of Pharmacy, Nashville, Tennessee.; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, Tennessee., Moreno-Villagomez J; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.; Facultad de Estudios Superiores Iztacala, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico., Maulion C; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut., Bellumkonda L; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut., Chang J; Section of General Internal Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.; Department of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut., Field MP; Elemental Scientific, Omaha, Nebraska., Wiederin DR; Elemental Scientific, Omaha, Nebraska., Butler J; Baylor Scott and White Research Institute, Dallas, Texas., Collins SP; Department of Emergency Medicine, Geriatric Research, Education and Clinical Center (GRECC), Vanderbilt University Medical Center and Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee., Turner JM; Division of Nephrology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut., Wilson FP; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.; Clinical and Translational Research Accelerator, Yale University School of Medicine, New Haven, Connecticut., Inzucchi SE; Section of Endocrinology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut., Wilcox CS; Division of Nephrology and Hypertension Center, Georgetown University, Washington, DC., Ellison DH; Oregon Clinical and Translational Research Institute, Oregon Health and Science University, Portland, Oregon., Testani JM; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut. |
| Source: | Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2024 Feb 01; Vol. 35 (2), pp. 189-201. Date of Electronic Publication: 2023 Dec 11. |
| Publication Type: | Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Wolters Kluwer Health, on behalf of the American Society of Nephrology Country of Publication: United States NLM ID: 9013836 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-3450 (Electronic) Linking ISSN: 10466673 NLM ISO Abbreviation: J Am Soc Nephrol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
